ABSTRACT
Transthyretin amyloidosis (ATTR) variant is a life-threatening hereditary disease predominantly affecting the peripheral nervous system and heart. Tafamidis, which prevents the deposition of amyloid by stabilizing transthyretin, is available for the treatment of neuropathy and cardiomyopathy of ATTR. However, whether tafamidis could eliminate established amyloid deposits and improve cardiac function remains unknown. We reported a case of regression of left ventricular hypertrophy after tafamidis therapy in a patient with an ATTR variant. J. Med. Invest. 69 : 320-322, August, 2022.
Subject(s)
Amyloid Neuropathies, Familial , Prealbumin , Amyloid Neuropathies, Familial/complications , Amyloid Neuropathies, Familial/drug therapy , Benzoxazoles , Humans , Hypertrophy, Left Ventricular/drug therapy , Hypertrophy, Left Ventricular/etiology , Prealbumin/geneticsABSTRACT
BACKGROUND: It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown. METHODS AND RESULTS: We enrolled 57 patients with acute VTE with/without pulmonary embolism treated with edoxaban (n=37) or warfarin (n=20) in a clinical setting. Before treatment and 2 weeks after treatment, we evaluated thrombotic burden using ultrasound or computed tomography angiography. We also evaluated thrombin generation, represented by prothrombin fragment F1+2; thrombus degradation, represented by D-dimer; and levels of anticoagulants, including protein C, protein S, and antithrombin III. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer. Edoxaban treatment preserved protein C and protein S levels. In contrast, warfarin decreased protein C and protein S levels. Neither treatment affected antithrombin III. CONCLUSIONS: Edoxaban improves VTE while preserving protein C and protein S levels, thereby indicating that edoxaban improves thrombotic burden while maintaining levels of anticoagulants.
Subject(s)
Anticoagulants/pharmacology , Protein C/drug effects , Protein S/drug effects , Pyridines/pharmacology , Thiazoles/pharmacology , Venous Thromboembolism/drug therapy , Acute Disease , Aged , Antithrombin III/drug effects , Female , Humans , Male , Middle Aged , Pulmonary Embolism/drug therapy , Treatment Outcome , Venous Thromboembolism/blood , Warfarin/pharmacologySubject(s)
Abscess , Echocardiography , Immunocompromised Host , Nocardia Infections , Nocardia , Pericarditis , Pericardium , Tomography, X-Ray Computed , Abscess/diagnostic imaging , Abscess/microbiology , Abscess/pathology , Aged, 80 and over , Female , Humans , Nocardia Infections/diagnostic imaging , Nocardia Infections/pathology , Pericarditis/diagnostic imaging , Pericarditis/microbiology , Pericarditis/pathology , Pericardium/diagnostic imaging , Pericardium/microbiology , Pericardium/pathologyABSTRACT
BACKGROUND: Uremic toxin has emerged as an important determinant of cardiovascular risk. The aim of this study was to examine the relationship between serum uremic toxin and coronary plaque composition on integrated backscatter intravascular ultrasound (IB-IVUS). METHODS AND RESULTS: IB-IVUS was performed in 47 patients with planned treatment for angina pectoris. Non-culprit intermediate plaque analyzed in this study had to be >5 mm apart from the intervention site. 3-D IB-IVUS analysis was performed to determine percent lipid volume (LV) and fibrous volume (FV). We also measured serum uremic toxins (indoxyl sulfate [IS], asymmetric dimethylarginine [ADMA], and p-cresol [PC]). Glomerular filtration rate correlated with IS (r=-0.329, P=0.04), but did not correlate with ADMA or PC. Percent LV correlated with IS (r=0.365, P=0.02), but did not correlate with ADMA or PC. Percent FV also correlated with IS (r=-0.356, P=0.03), but did not correlate with ADMA or PC. On multivariate regression, only IS was associated with percent LV (r=0.359, P=0.04) and percent FV (r=-0.305, P=0.04) independently of potentially confounding coronary risk factors. CONCLUSIONS: Among the uremic toxins, serum IS might be a novel useful biomarker to detect and monitor lipid-rich coronary plaque on IB imaging.
Subject(s)
Coronary Artery Disease , Indican/blood , Plaque, Atherosclerotic , Ultrasonography, Interventional , Aged , Arginine/analogs & derivatives , Arginine/blood , Biomarkers , Coronary Artery Disease/blood , Coronary Artery Disease/diagnostic imaging , Female , Humans , Male , Middle Aged , Plaque, Atherosclerotic/blood , Plaque, Atherosclerotic/diagnostic imaging , Risk FactorsABSTRACT
A 71-year-old female had worked on a farm in the mountains and noticed itching of the left 3rd toe. She visited a local hospital due to a color change to purple in this area. Attachment of a tick was observed between the left 2nd and 3rd toes, and it was extracted. However, due to persistent pain, she was referred to our department of cardiovascular medicine for close examination and treatment. Lower extremity angiography showed that vascular visualization was poor in the area supplied by the arteries distal to the tick bite site, but the other blood vessels of the toe were clearly visualized. Toe amputation was performed and pathological examination of a surgical specimen revealed that most blood vessels near the necrosis were occluded by thrombi. We speculated that tick bite reactions were associated with thrombogenic vasculopathy. This report shows a patient who developed toe necrosis due to poor blood circulation after an interdigital tick bite.
